soul trial oral semaglutide cardiovascular outcomes 2024 results mace PDF) Effects of on in individuals with type 2 diabetes and established atherosclerotic cardiovascular disease and/or chronic kidney disease: Design and baseline characteristics of SOUL, a randomized Semaglutide cardiovascular outcomes align more

this macro doesnt spike your blood sugar and can slow the digestion of carbs (like rice and potatoes)

Lean Mass Trajectory

[11] [16] Clinical observations suggest that semaglutide may improve liver enzyme levels in many patients, particularly those with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD)

Dejgaard TF, Frandsen CS, Hansen TS et al (2016) Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial

You're not writing a case study